Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $2.00 price target on the stock.
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results